Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543506 | 0.85 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13461881 | 0.85 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3543503 | 0.85 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14563334 | 0.84 | MEN1 (0.42) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1186911 | 0.83 | MEN1 (0.52) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12021301 | 0.82 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4680751 | 0.82 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4680747 | 0.82 | MEN1 (0.41) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11767308 | 0.78 | ELANE (0.52) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5725421 | 0.77 | LSS (0.49) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | MEN1 1317/4885KMT2A 1619/4885NPC1 295/4885 |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | MEN1 991/4885KMT2A 2325/4885NPC1 1066/4885 |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | MEN1 991/4885KMT2A 2325/4885NPC1 1066/4885 |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | IAPP, INSR, GPR119 | MEN1 1119/4885KMT2A 3271/4885NPC1 574/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | MEN1 684/4885KMT2A 1240/4885NPC1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.